Related Experiment Video
Updated: Feb 23, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
[Acute and chronic heart failure]
K-P Kresoja1,2, G Schmidt1, B Kherad1
1Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum (CVK), Charité - Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Deutschland.
Insights
New heart failure guidelines include sacubitril/valsartan (LCZ 696) and address comorbidities. Updated recommendations also cover iron therapy, cardiac devices, and mechanical support for acute heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current chronic heart failure (CHF) initial therapy includes diuretics, ACE inhibitors, beta-blockers, and MRAs.
- The 2016 European Society of Cardiology (ESC) guidelines introduced novel therapeutic agents for CHF.
Purpose of the Study:
- To review recent advancements in the medical and device therapy of chronic and acute heart failure.
- To highlight the role of new agents like sacubitril/valsartan (LCZ 696) and address comorbidities.
Main Methods:
- Review of new European Society of Cardiology (ESC) guidelines.
- Analysis of subgroup data for sacubitril/valsartan (LCZ 696).
- Inclusion of data on intravenous iron, cardiac devices, and mechanical circulatory support.
Main Results:
- Sacubitril/valsartan (LCZ 696) demonstrates benefits across various comorbidities including renal insufficiency, diabetes, and hypotension.
- New data support intravenous iron substitution and provide updated indications for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT).
- Medical therapy for acute heart failure remains limited, with mechanical circulatory support, such as extracorporeal membrane oxygenation (ECMO), recommended for non-responders.
Conclusions:
- Angiotensin-receptor-neprilysin inhibitors represent a significant advancement in chronic heart failure management.
- Comprehensive updates address device therapy and novel treatments for heart failure patients with complex conditions.
- Mechanical circulatory support is crucial for managing acute heart failure when medical therapy fails.
Abstract:
The initial therapy of chronic heart failure is still based on diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and in specific cases mineralocorticoid receptor antagonists. The new European Society of Cardiology (ESC) guidelines published in 2016 introduced angiotensin-receptor-neprilysin inhibitors, such as sacubitril/valsartan (LCZ 696) as new therapeutic agents in patients with chronic and progressive heart failure. New subgroup analyses for LCZ 696 have been published showing a beneficial effect in the context of various comorbidities, such as renal insufficiency, diabetes and hypotension. Furthermore, new data are available on intravenous iron substitution in chronic heart failure and on the indications for implantable converter defibrillators, cardiac resynchronization therapy and other cardiac devices. Medicinal therapy of acute heart failure is still limited. For patients who cannot be treated with medicinal therapy, mechanical circulatory support, such as extracorporeal membrane oxygenation (ECMO) should be recommended.
Related Concept Videos
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

